Petros pharmaceuticals developing first-in-industry saas platform utilizing ai and electronic health records intended to facilitate rx-otc switches

Licensable platform intended to facilitate industry compliance with president trump's recent executive order to expand access to medicines through otc approvals under his make america healthy again (maha) initiative new york, ny / access newswire / may 1, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces a concerted effort toward evolving into a smart healthcare technology company through the development of a saas platform designed to complement its proprietary web application (also known as a software as a medical device, or samd). the licensable platform is being designed to integrate key cloud-based components, including ai, electronic health records, cybersecurity and others to provide potential prescription treatments and pharmaceutical sponsors with a commercially viable and enterprise scaled platform.
PTPI Ratings Summary
PTPI Quant Ranking